Abstract

Akeega (Janssen), a fixed-dose combination of the oral poly(ADP-ribose) polymerase (PARP) inhibitor niraparib (Zejula) and the antiandrogen abiraterone acetate (Zytiga, and others), has been approved by the FDA for use in combination with prednisone for treatment of adults with deleterious or suspected deleterious BRCA-mutated (BRCAm) metastatic castration-resistant prostate cancer (mCRPC).

Full Text

Published Version
Open DOI Link

Topics from this Paper

  • Metastatic Castration-resistant Prostate Cancer
  • Inhibitor Niraparib
  • Use In Combination
  • poly(ADP-ribose) Polymerase
  • BRCA-mutated
    • + Show 5 more

Create a personalized feed of these topics

Get Started

Get access to 115M+ research papers

Discover from 40M+ Open access, 2M+ Pre-prints, 9.5M Topics and 32K+ Journals.

Sign Up Now! It's FREE

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Predicting Response and Recognizing Resistance: Improving Outcomes in Patients With Castration-resistant Prostate Cancer
  • Urology
  • Nov 1, 2017
Relevant
Not Relevant
Systematic Literature Review of the Epidemiology of Advanced Prostate Cancer and Associated Homologous Recombination Repair Gene Alterations
  • Journal of Urology
  • Apr 1, 2021
Relevant
Not Relevant
PARP inhibitor and chemotherapy combination trials for the treatment of advanced malignancies: does a development pathway forward exist?
  • Annals of Oncology
  • Mar 1, 2017
Relevant
Not Relevant
Continuing enzalutamide with docetaxel in castration-resistant prostate cancer
  • The Lancet Oncology
  • Nov 1, 2022
Relevant
Not Relevant
Combining next-generation hormonal therapy with PARP inhibition in metastatic castration-resistant prostate cancer.
  • Lancet (London, England)
  • Jun 2, 2023
Relevant
Not Relevant
Second-line treatment options in metastatic castration-resistant prostate cancer: A comparison of key trials with recently approved agents
  • Cancer Treatment Reviews
  • Feb 1, 2014
Relevant
Not Relevant
Poly (ADP-ribose) polymerase (PARP) inhibitors for the treatment of advanced germline BRCA2 mutant prostate cancer
  • Annals of Oncology
  • May 1, 2013
Relevant
Not Relevant
Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART II
  • Journal of Urology
  • Jan 1, 2021
Relevant
Not Relevant
PARP-inhibitor-induced synthetic lethality for acute myeloid leukemia treatment
  • Experimental Hematology
  • Oct 1, 2016
Relevant
Not Relevant
Cancer treatment: at what cost?
  • Nursing and Residential Care
  • Mar 2, 2015
Relevant
Not Relevant
Poly(ADP-Ribose) Polymerases
  • The American Journal of Pathology
  • Feb 1, 2016
Relevant
Not Relevant
Poly(ADP-ribose) polymerase inhibitors in prostate cancer: a cornerstone in precision oncology
  • Pharmacogenomics
  • Dec 1, 2021
Relevant
Not Relevant
The Promise of Circulating Tumor Cells in Metastatic CRPC
  • Oncology Times
  • Jun 1, 2018
Relevant
Not Relevant
Pulmonary metastasis secondary to abiraterone-resistant prostate cancer with homozygous deletions of BRCA2: First Japanese case.
  • Jan 1, 2021
Relevant
Not Relevant
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer. Part II—2020 Update: Treatment of Relapsing and Metastatic Prostate Cancer
  • European Urology
  • Feb 1, 2021
Relevant
Not Relevant
READ MORE FROM

The Medical letter on drugs and therapeutics

Sulbactam/durlobactam (Xacduro) for Acinetobacter pneumonia.
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
Shockwave therapy for erectile dysfunction.
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
In brief: GI effects of GLP-1 receptor agonists.
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
Ritlecitinib (Litfulo) for severe alopecia areata.
Open Access
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
Addendum.
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
Etrasimod (Velsipity) for ulcerative colitis.
Open Access
Just Published
  • The Medical letter on drugs and therapeutics
  • Nov 27, 2023
Relevant
Not Relevant
COVID-19 update: New Novavax vaccine formulation for 2023-2024.
  • The Medical letter on drugs and therapeutics
  • Nov 13, 2023
Relevant
Not Relevant
Correction.
  • The Medical letter on drugs and therapeutics
  • Nov 13, 2023
Relevant
Not Relevant
In brief: Empagliflozin (Jardiance) for chronic kidney disease.
  • The Medical letter on drugs and therapeutics
  • Nov 13, 2023
Relevant
Not Relevant
Antiviral drugs for influenza for 2023-2024.
  • The Medical letter on drugs and therapeutics
  • Nov 13, 2023
Relevant
Not Relevant